3.4.23.24	Acquired Immunodeficiency Syndrome	https://pubmed.ncbi.nlm.nih.gov/7952656/	Structure-assisted design of nonpeptide human immunodeficiency virus-1 protease inhibitors.	causal interaction	1	
3.4.23.24	Acquired Immunodeficiency Syndrome	https://pubmed.ncbi.nlm.nih.gov/10395861/	In vitro and in vivo anticandidal activity of human immunodeficiency virus protease inhibitors.	causal interaction	4	
3.4.23.24	Acquired Immunodeficiency Syndrome	https://pubmed.ncbi.nlm.nih.gov/15305695/	[Highly Active AntiRetroviral Therapy and cryptosporidiosis]	causal interaction	2	
3.4.23.24	Acquired Immunodeficiency Syndrome	https://pubmed.ncbi.nlm.nih.gov/30393404/	Syntheses of FDA Approved HIV Protease Inhibitors.	causal interaction	3	
3.4.23.24	Acquired Immunodeficiency Syndrome	https://pubmed.ncbi.nlm.nih.gov/32601166/	The FDA-Approved Drug Nelfinavir Inhibits Lytic Cell-Free but Not Cell-Associated Nonlytic Transmission of Human Adenovirus.	causal interaction	2	
3.4.23.24	Acquired Immunodeficiency Syndrome	https://pubmed.ncbi.nlm.nih.gov/10395861/	In vitro and in vivo anticandidal activity of human immunodeficiency virus protease inhibitors.	therapeutic application	4	
3.4.23.24	Acquired Immunodeficiency Syndrome	https://pubmed.ncbi.nlm.nih.gov/10770752/	Enhanced extracellular production of aspartyl proteinase, a virulence factor, by Candida albicans isolates following growth in subinhibitory concentrations of fluconazole.	therapeutic application	1	
3.4.23.24	Acquired Immunodeficiency Syndrome	https://pubmed.ncbi.nlm.nih.gov/15305695/	[Highly Active AntiRetroviral Therapy and cryptosporidiosis]	therapeutic application	4	
3.4.23.24	Acquired Immunodeficiency Syndrome	https://pubmed.ncbi.nlm.nih.gov/30393404/	Syntheses of FDA Approved HIV Protease Inhibitors.	therapeutic application	4	
3.4.23.24	Acquired Immunodeficiency Syndrome	https://pubmed.ncbi.nlm.nih.gov/32601166/	The FDA-Approved Drug Nelfinavir Inhibits Lytic Cell-Free but Not Cell-Associated Nonlytic Transmission of Human Adenovirus.	therapeutic application	4